- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Jazz Pharmaceuticals Plc
+ Add to WatchlistJAZZ:US
63.7500 USD 0.7500 1.19%As of 20:10:00 ET on 05/24/2013.
Snapshot for Jazz Pharmaceuticals Plc (JAZZ)
| Open: | 62.6300 | Day's Range: | 62.4600 - 65.0000 | Volume: | 1,209,064 |
|---|---|---|---|---|---|
| Previous Close: | 63.7500 | 52wk Range: | 40.3800 - 65.0000 | 1-Yr Rtn: | +39.01% |
Key Statistics for JAZZ
| Current P/E Ratio (ttm) | 13.0635 |
|---|---|
| Estimated P/E(12/2013) | 10.4082 |
| Relative P/E vs. SPX | 0.8110 |
| Earnings Per Share (USD) (ttm) | 4.8800 |
| Est. EPS (USD) (12/2013) | 6.1250 |
| Est. PEG Ratio | 0.5551 |
| Market Cap (M USD) | 3,699.76 |
| Shares Outstanding (M) | 58.04 |
| 30 Day Average Volume | 942,641 |
| Price/Book (mrq) | 3.2289 |
| Price/Sale (ttm) | 5.3807 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for JAZZ
Company Profile & Key Executives for JAZZ
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.
| Bruce C CozaddChairman/CEO/Co-Founder | Seamus C MulliganChief Business Officer |
| Kathryn E Falberg "Kate"Exec VP/CFO | Russell J CoxExec VP/Chief Commercial Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
JAZZ News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page